Business
Aadi Bioscience to Present Multiple Posters at the American Association for Cancer Research (AACR) Annual Meeting 2024
LOS ANGELES, March 5, 2024 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing
About this update from Whitehawk Therapeutics, Inc.
[{"type":"text","content":"LOS ANGELES, March 5, 2024 /PRNewswire/ -- Aadi Bioscience, Inc. (NASDAQ: AADI), a biopharmaceutical company focused on developing and commercializing precision therapies for patients with mTOR-driven cancers, today announced poster presentations at the 2024 American Association for Cancer Research (AACR), taking place April 5-10, 2024, in San Diego, CA.\nAACR poster presentation details are below:\nTitle: \"Evaluation of nab-sirolimus in combination with fulvestrant or PI3K pathway inhibitors to overcome resistance in breast cancer cell lines\"Session Title: Reversal of Drug Resistance 2Location: Poster Section 25, Board Number 6Abstract Number: 7196Date/Time: Wednesday Apr 10, 2024, 9:00 AM - 12:30 PMPresenting Author: Shihe Hou, PhD\nTitle: \"Correlation of nab-sirolimus tumor drug levels and improved tumor suppression in KRAS G12C non-small cell lung cancer xenografts treated with nab-sirolimus in combination with KRAS inhibitors\"Session Title: Targeting Kinase and ERK PathwaysLocation: Poster Section 46, Board Number 3Abstract Number: 6486Date/Time: Tuesday Apr 9, 2024 1:30 PM - 5:00 PMPresenting Author: Shihe Hou, PhD\nMore information can be found on the AACR meeting website.\nAbout Aadi Bioscience, Inc.\nAadi is a commercial-stage biopharmaceutical company focused on precision therapies for cancers to bring transformational therapies to cancer patients with alterations in the mTOR pathway, a key regulator of cell growth and cancer progression. Aadi received FDA approval and has commercialized FYARRO® for the treatment of adult patients with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor (PEComa).\nAadi has also initiated clinical trials of nab-sirolimus as a single agent or in combination for the treatment of other mTOR-driven cancers. PRECISION 1 (NCT05103358), a Phase 2 tumor-agnostic registration-intended trial in mTOR inhibitor-naïve malignant solid tumors harboring TSC1 or TSC2 inactivating alterations is currently enrolling in the US and globally. A multicenter, open-label, single-arm Phase 2 study of nab-sirolimus in combination with letrozole is currently enrolling patients with advanced or recurrent endometrioid endometrial cancer (NCT05997017); nab-sirolimus is also being investigated as a single agent in an open-label, single-arm, Phase 2 trial for the treatment of p...